为肝细胞癌武装 GPC3 CAR-T 细胞：多少才足够，下一步是什么？
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Tremelimumab 联合 Durvalumab 治疗晚期肝细胞癌中的 WNT/β-catenin 信号通路与 CD8+ TIL（肿瘤浸润淋巴细胞）
英文原题：WNT/β-catenin Signaling and CD8+ Tumor-infiltrating Lymphocytes in Tremelimumab Plus Durvalumab for Advanced Hepatocellular Carcinoma.
查看英文原题
WNT/β-catenin Signaling and CD8+ Tumor-infiltrating Lymphocytes in Tremelimumab Plus Durvalumab for Advanced Hepatocellular Carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
尽管本研究纳入的患者数量较少，但研究结果提示，tremelimumab 联合 durvalumab 的疗效可能受 WNT/β-catenin 信号通路和 CD8⁺ TIL 浸润的影响。
中文摘要
患者与方法
15例接受肿瘤活检的HCC患者，根据WNT/β-连环蛋白信号活化状态及CD8+ TIL浸润情况分为三组，并评估各组治疗应答。
结果
4例患者为WNT/β-连环蛋白信号失活且CD8+ TIL浸润水平高；4例患者为信号活化且CD8+ TIL浸润水平低；另7例患者为信号活化且CD8+ TIL浸润水平高，或信号失活且CD8+ TIL浸润水平低。WNT/β-连环蛋白信号失活且CD8+ TIL浸润水平高组的缓解率较高，而信号活化且CD8+ TIL浸润水平低组的缓解率较低。
结论
尽管本研究患者数量较少，结果提示曲雷利木单抗联合度伐利尤单抗的疗效可能受到WNT/β-连环蛋白信号和CD8+ TIL浸润的影响。
展开英文摘要原文
PATIENTS AND METHODS
Fifteen HCC patients who underwent tumor biopsies were classified into three groups based on WNT/ -catenin signal activation and CD8+ TIL infiltration. The clinical responses to treatment in the groups were evaluated.
RESULTS
Four patients had HCC with WNT/ -catenin signal inactivation and high-level CD8+ TIL infiltration, four patients had HCC with WNT/ -catenin signal activation and low-level CD8+ TIL infiltration, and seven patients had WNT/ -catenin signal activation and high-level CD8+ TIL infiltration or WNT/ -catenin signal inactivation and low-level CD8+ TIL infiltration. A better response rate was observed in the WNT/ -catenin signal inactivation and high-level CD8+ TIL infiltration group, and a worse response rate was observed in the WNT/ -catenin signal activation and low-level CD8+ TIL infiltration group.
CONCLUSION
Although the present study involved a small number of patients, the findings suggest that the efficacy of tremelimumab plus durvalumab may be affected by WNT/ -catenin signaling and CD8+ TIL infiltration.
论文信息
- 作者
- Kuwano A、Tanaka K、Takahira J、Suzuki H、Ohishi Y、Motomura K
- 第一作者单位
- Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan.Japan
- 通讯作者单位
- Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan; ktanakah8@aih-net.com.Japan
- 期刊
- In vivo (Athens, Greece)2024 Nov-Dec
- 原文标识
- PubMed 39477407 · DOI 10.21873/invivo.13757
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →